Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: glucocorticoid

Glucocorticoids Increase Infections, Mortality

Arthritis & Rheumatology  |  August 19, 2024

Figueroa-Parra et al. set out to evaluate the effect of glucocorticoid regimens on renal response, infections and mortality rates among patients with lupus nephritis (LN). The researchers analyzed the control arms of randomized clinical trials and found a higher exposure to glucocorticoids during the initial treatment of LN was associated with better renal outcomes, at the cost of increased infections and mortality.

Filed under:Biologics/DMARDsConditions Tagged with:Arthritis & RheumatologyGlucocorticoidsLupus nephritismortalityRenal

3 AC&R Study Summaries: Prescribing Patterns, PMR & Glucocorticoids, & Infection Screening

Arthritis Care & Research  |  February 9, 2024

A Shift in Prescribing Patterns Safety issues prompt discontinuation of tofacitinib By Stephanie Song, MD, & Joshua F. Baker, MD, MSCE Why was this study done? The ORAL Surveillance study highlighted risks of cardiac events, thromboembolism (VTE) and malignancy associated with use of Janus kinase inhibitors (JAKi). We sought to determine the impact of safety…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch ReviewsResearch RheumRheumatoid Arthritis Tagged with:GlucocorticoidsInfectionJAK inhibitorsPolymyalgia RheumaticaReading Rheumsteroid-sparing therapiesTofacitinib

FDA Approves Sarilumab for Adults with Glucocorticoid-Resistant Polymyalgia Rheumatica

Michele B. Kaufman, PharmD, BCGP  |  January 25, 2024

On Feb. 28, 2023, the U.S. Food & Drug Administration (FDA) approved sarilumab (Kevzara) for the treatment of adults with polymyalgia rheumatica (PMR) for whom glucocorticoids have proved inadequate or who cannot tolerate a glucocorticoid taper.1,2 Sarilumab is an interleukin (IL) 6 receptor antagonist. In May 2017, the FDA initially approved the agent for the…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:glucocorticoid resistantIL-6IL-6 inhibitorsPMR FocusRheumPolymyalgia RheumaticaResearch Reviewsarilumab

Reduced-Dose Glucocorticoids for GPA & Microscopic Polyangiitis

Arthritis & Rheumatology  |  December 1, 2023

SAN DIEGO—In a study titled Real-Life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis, Nagle et al. evaluated the efficacy and safety of the reduced-dose glucocorticoid regimen in a real-world setting. Background/Purpose Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with…

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:AAVAAV FocusRheumACR Convergence 2023Arthritis & RheumatologyCorticosteroidsgranulamatosis with polyangiitismicroscopic polyangiitis (MPA)Research

Glucocorticoids in RA

David S. Pisetsky, MD, PhD  |  November 7, 2023

The historical & continuing roles of glucocorticoids in the treatment of RA are discussed. 

Filed under:Education & TrainingRheumatoid Arthritis Tagged with:GlucocorticoidsRA Resource CenterRheumatoid Arthritis (RA)

ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline

Ruth Jessen Hickman, MD  |  October 10, 2023

The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesGlucocorticoid-Induced Osteoporosis

Glucocorticoid Use at Any Dose Increases Fracture Risk

Arthritis & Rheumatology  |  September 26, 2023

The accepted wisdom is that the negative effects of glucocorticoids on bone depend on the dose and treatment duration. Adami et al. conducted this study to determine, in a real-life setting, the risk of fragility fracture associated with the dose of glucocorticoids in patients with inflammatory rheumatic musculoskeletal diseases.

Filed under:Biologics/DMARDsDrug Updates Tagged with:Arthritis & Rheumatologybone lossGlucocorticoidsOsteoporosisResearch

FDA Approves Sarilumab for the Treatment of Adults with Glucocorticoid-Resistant PMR

Michele B. Kaufman, PharmD, BCGP  |  March 14, 2023

Sarilumab is now FDA approved to treat adults with polymyalgia rheumatica who have had an inadequate response to glucocorticoids or who cannot tolerate a glucocorticoid taper. This new indication is based on results from the multicenter, phase 3 SAPHYR trial.

Filed under:Drug Updates Tagged with:FDA approvalglucocorticoidPolymyalgia RheumaticasarilumabU.S. Food and Drug Administration (FDA)

Glucocorticoid Use May Result in Loss of Bone Mineral Density

Michele B. Kaufman, PharmD, BCGP  |  March 8, 2023

Adami et al. examined the fracture risk associated with glucocorticoid treatment in women with inflammatory rheumatic musculoskeletal diseases, finding that low-dose glucocorticoid use may result in significant bone mineral density loss in patients who are not on anti-osteoporotic drugs.

Filed under:ACR ConvergenceDrug Updates Tagged with:ACR Convergence 2022bone lossbone mineral density (BMD)fracture riskGlucocorticoidsinflammatory musculoskeletal disease

Sarilumab Approved for the Treatment of Adults with Glucocorticoid-Resistant PMR

Keri Losavio  |  March 3, 2023

First described in 1888, polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 Until this week, no therapies for PMR had been approved by the U.S. Food & Drug Administration (FDA).2 Tuesday, Sanofi announced sarilumab (Kevzara) has been approved by the U.S. Food & Drug Administration for the…

Filed under:ConditionsDrug UpdatesOther Rheumatic Conditions Tagged with:Polymyalgia Rheumaticasarilumab

  • 1
  • 2
  • 3
  • …
  • 56
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences